Document is current
Any future updates will be listed below
-
Authors
Fagiolini, Andrea
Grošelj, Lea Dolenc
Šagud, Marina
Silić, Ante
Latas, Milan
Miljević, Čedo D.
Cuomo, Alessandro
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 14 April 2025
First Online: 22 May 2025
Declarations
:
: A. Fagiolini: Received fees or funding from Angelini, Aspen, Biogen, Boehringer Ingelheim, Janssen, Lundbeck, Neuraxpharm, Otsuka, Pfizer, Recordati, and Viatris. Milan Latas: In the last three years, presented lectures for Angelini, Gedeon Richter, Galenika, Johnson & Johnson, and Krka Farma. Čedo D. Miljevic: Has been a speaker for Actavis, Bonifar, Boehringer Ingelheim, Galenika, Goodwill Pharma, Janssen, Mylan, Pfizer, and Remedica. Lea Dolenc Grošelj: Declares no competing interests. Marina Sagud: In the last three years, presented lectures for Angelini, Belupo, Gedeon Richter, Johnson & Johnson, Krka Farma d.o.o., Lundbeck, Pliva d.o.o., and Viatris; participated in clinical trials as a principal investigator for Boehringer Ingelheim; and is a member of the advisory board of Lundbeck and Pliva. Ante Silic: Declares no competing interests. A. Cuomo: Received fees or funding from Angelini, GlaxoSmithKline, Italfarmaco, Lundbeck, Janssen, Mylan, Neuraxpharm, Otsuka, Pfizer, Recordati, Sanofi Aventis, and Viatris.
